Somatostatin Analogues in Neuroendocrine Tumors

Author: Matthew H. Kulke MD
View More View Less

Matthew H. Kulke, MD, is Director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute and an associate professor of medicine at Harvard Medical School. Dr. Kulke serves as Chair of the NCCN Neuroendocrine Tumors Guidelines Panel.

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.

  • 1.

    Kulke MH, Shah MH, Benson AB et al.. NCCN Clinical Practice Guidelines in Oncology for Neuroendocrine Tumors. Version 1.2015. Available at: www.NCCN.org. Accessed February 24, 2016.

    • Search Google Scholar
    • Export Citation
  • 2.

    Kvols LK, Moertel CG, O'Connell MJ et al.. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med 1986;315:663666.

    • Search Google Scholar
    • Export Citation
  • 3.

    Rubin J, Ajani J, Schirmer W et al.. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600606.

    • Search Google Scholar
    • Export Citation
  • 4.

    Rinke A, Muller HH, Schade-Brittinger C et al.. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:46564663.

    • Search Google Scholar
    • Export Citation
  • 5.

    Ruszniewski P, Ish-Shalom S, Wymenga M et al.. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004;80:244251.

    • Search Google Scholar
    • Export Citation
  • 6.

    Vinik A, Wolin EM, Audry H et al.. ELECT: a phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs) [abstract]. J Clin Oncol 2014;32:Abstract 268.

    • Search Google Scholar
    • Export Citation
  • 7.

    Caplin ME, Pavel M, Ćwikła JB et al.for the CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371:224233.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1723 510 42
PDF Downloads 357 209 22
EPUB Downloads 0 0 0